OmniAb, Inc. (OABI)

Market Cap	419.91M
Revenue (ttm)	20.41M
Net Income (ttm)	-63.02M
Shares Out	121.01M
EPS (ttm)	-0.62
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,829
Open	3.490
Previous Close	3.500
Day's Range	3.450 - 3.550
52-Week Range	3.430 - 6.720
Beta	0.38
Analysts	Strong Buy
Price Target	9.00 (+159.37%)
Earnings Date	Nov 12, 2024

About OABI

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company’s technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners’ drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 106
• Stock Exchange: NASDAQ
• Ticker Symbol: OABI
• Website: https://www.omniab.com

Financial Performance

In 2023, OmniAb's revenue was $34.16 million, a decrease of -42.17% compared to the previous year's $59.08 million. Losses were -$50.62 million, 126.6% more than in 2022.

Analyst Forecast

According to 4 analysts, the average rating for OABI stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 159.37% from the latest price.

Price Target

$9.0

(159.37% upside)

Analyst Consensus: Strong Buy